Merck's sac-TMT beat chemotherapy in first-line PD-L1-negative lung cancer — the emerging answer to Keytruda's patent cliff. Plus: Europe approves Novo Nordisk's oral Wegovy ahead of Eli Lilly, Sanofi sues Pfizer and Moderna over mRNA patents, Bora and Insilico Medicine ink a $2.5B AI alliance, the FDA resumes publishing complete response letters, Q32 Bio surges on alopecia areata data, and Veradermics posts a Phase 2 win in female pattern hair loss.
Auto-generated from the episode script. Deal names link to their scorecard in the database.
Merck's China-partnered ADC just beat chemotherapy in front-line lung cancer — and Wall Street is calling it proof that the answer to Keytruda's patent cliff is already in hand.
Meanwhile Europe clears Novo's Wegovy pill ahead of Lilly, Sanofi drags Pfizer and Moderna into an mRNA patent fight, and the FDA quietly turns the rejection-letter spigot back on. Busy Wednesday. Let's get into it.
Welcome to The Pharma Closeout for Wednesday, July 15th, 2026. I'm Alex Mercer.
And I'm Maya Patel.
Start with Merck. Their TROP2 antibody-drug conjugate, sac-TMT — partnered with China's Kelun-Biotech — hit its primary endpoint in the Phase 3 OptiTROP-Lung06 study. First-line, PD-L1-negative, non-squamous lung cancer. They pulled the chemo backbone out, dropped sac-TMT in alongside Keytruda, and beat chemo-plus-Keytruda on progression-free survival, with a positive survival trend. The street's verdict was one phrase: direct proof-of-concept. Merck's own word is bigger — cornerstone.
And the cornerstone label earns it here, for a specific reason. PD-L1-negative is the population that gets the least out of checkpoint therapy — the patients where Keytruda alone was never going to carry the day. So the clever move isn't the drug they added. It's the drug they took out. Per Kelun's release, this is the world's first Phase 3 showing an ADC plus a checkpoint inhibitor beating standard of care in first-line, driver-negative, PD-L1-negative disease. They cracked a real bottleneck.
And the timing is everything. Keytruda's loss of exclusivity is the biggest cliff in this industry, and Merck has spent two years telling investors exactly how they fill it. Sac-TMT is the name they keep repeating. At ASCO in May, the PD-L1-positive study cut progression risk by 65% versus Keytruda alone. Now they've got the negative population too. That's the blueprint, both halves of it.
OK, but here's my issue with the "answer to the cliff" framing. Sac-TMT didn't replace Keytruda in this trial — it's dosed alongside it. What it replaced was the pemetrexed-and-platinum chemo. So this isn't a successor molecule. It's a chemo-replacement strategy that keeps the Keytruda franchise alive inside a brand-new regimen.
That's fair — I'll take the correction. So the read isn't "new drug buries old blockbuster."
Right. It's that Merck extends the Keytruda economics past the cliff by rebuilding the regimen around it. The molecule that dies here isn't Keytruda — it's the chemotherapy. And here's the thread they didn't lead with. The survival data is a trend, not a result. In this population, progression-free survival buys you the headline. Overall survival buys you the guidelines and the reimbursement. Until that curve matures, this is a very strong signal — not a closed case.
The competitive read: if you run commercial strategy anywhere in the TROP2 or lung space — Gilead, Daiichi, AstraZeneca — Merck just proved the ADC-plus-checkpoint combo works in the hardest first-line population, and the China data is now the template for the global program. Every launch model in front-line lung moved this morning.
Which sets up the deal side, because the other China story today is a check. AstraZeneca is paying $600 million upfront for rights to Dizal's lung cancer pill — more Chinese-origin science landing in a Western pipeline. But the eye-popping number belongs to an AI alliance, and it's structurally strange enough that I want to bring in Marcus Webb.
Bora Pharmaceuticals and Insilico Medicine. Potential value could exceed two and a half billion dollars — but "if fully implemented" is doing all the work in that sentence. What's genuinely new is the shape. An AI discovery platform married to a contract manufacturer, with a jointly built manufacturing venture as the endgame. I can't point to a clean precedent for a discovery-AI firm integrating this far down into biologics manufacturing. Insilico already has a Takeda collaboration worth up to about six hundred million. This is a different animal — they're building an operating company, not signing a licensing deal.
Marcus — does the milestone-heavy structure worry you or reassure you?
Reassures. Contingent-heavy terms mean neither side is betting the balance sheet on output nobody has seen yet. That's the disciplined way to build something without a map. Watch one thing: whether the manufacturing venture actually gets capitalized. That's the tell on whether this is real or a slide deck.
Good place to leave it. And the tape underneath is busy — AdvanCell pulled in $315 million for a Pluvicto challenger, Chai Discovery raised $400 million and tripled its valuation in seven months, and Lilly took a stake in Oura to support patients on GLP-1s. There's also a legal grenade: Sanofi sued Pfizer and Moderna over mRNA delivery patents, alleging the COVID shots infringe as many as ten of them.
And the Sanofi suit is the one to keep an eye on, because Moderna is already fighting this war on two fronts. It's litigating with BioNTech and Pfizer, and now Sanofi wants royalties on the technology that generated the company's entire revenue base. This isn't a nuisance filing — it's a claim on the foundation. The implication for anyone building on mRNA: the delivery IP is contested ground, and the licensing math on every next-gen program just got more expensive to model.
On the derm side, two clinical catalysts — Q32 Bio surged 60% on 36-week alopecia areata data that beat expectations, nearly two years after setbacks cratered the stock, and Veradermics posted a Phase 2 win in female pattern hair loss with its oral minoxidil, VDPHL01. Hair-count gains around 23 hairs per square centimeter, patient-reported improvement near 90%.
The Veradermics data is cleaner than the market's crediting — no cardiac adverse events of special interest, which is precisely the flag that has haunted off-label oral minoxidil for years. But the Q32 move is the tell. Immunology-in-dermatology appetite is real again, and it's rewarding the companies that survived a near-death cycle. Capital is flowing back into clinical-stage derm — and the acquirers are watching who reads out next.
On the regulatory front — the big one is Novo. The European Commission approved oral Wegovy today, once-daily semaglutide at 25 milligrams. Shares up about 2.6%. The OASIS 4 data behind it: 17% weight loss versus 3% on placebo, and roughly a third of patients clearing 20% or more. Per the EMA, this is the first oral weight-loss drug cleared in Europe — and it puts Novo into the EU oral market ahead of Lilly.
Which flips a board we've watched tilt Lilly's way for months. Lilly's orforglipron got its US nod back in April. But in Europe's oral segment, Novo's first through the door.
The sharper way to read it: injectable semaglutide already owns the brand and the prescriber habit. An oral version at these numbers isn't a new market — it's a moat around the old one. The durability question still hangs over every oral GLP-1. But if adherence holds, Novo just made switching harder for a Lilly rep in every European market at once.
Also worth noting on the regulatory side — the FDA turned the rejection-letter spigot back on. Fourteen fresh complete response letters posted, reversing the pause the agency put in place this month after a pharma-backed citizen petition. Recipients include Jiangsu Hengrui and Elevar. And in an Endpoints exclusive, the acting commissioner is walking back Makary's habit of making drug-review policy through journal articles.
That second thread is the structural one. Makary set the single-pivotal-trial default in a New England Journal piece — policy by publication. Rolling it back tells you the agency wants decisions made inside the normal process. For anyone modeling review timelines, predictability just went up.
And the reopened letter flow compounds it. When the agency publishes why it says no, every sponsor in that indication learns exactly where the bar sits. Transparency here isn't a courtesy — it's competitive intelligence, and it's back online.
Looking ahead. Two threads carry over. On Celcuity — approved yesterday — the catalyst we flagged still outranks the approval: their supplemental filing for the PIK3CA-mutant population, expected in Q3. That's what decides whether Celcuity stays a standalone or becomes a target. And J&J's restructuring — up to $750 million to reshape its pharma manufacturing footprint through fiscal 2029 — is the story under today's earnings dip. Oncology missed; immunology is covering the Stelara cliff.
And the readout I'm circling is the sac-TMT survival data. Everything Merck said this morning rests on a PFS win and a survival trend. If that curve matures the way the PD-L1-positive study hinted, this stops being a strong signal and becomes the new front-line standard. That's the one that settles it.
And that is your Pharma Closeout for Wednesday, July 15th — Merck's sac-TMT rewriting the front-line lung playbook, Novo's Wegovy pill beating Lilly into Europe, and the FDA back to publishing its rejection letters. This industry does not sit still. If you want to stay across this space, subscribe wherever you listen — we're back tomorrow.
We are. I'll be watching that sac-TMT survival curve and the Celcuity filing. Go have a great evening — see you tomorrow.
The daily Closeout in under 15 minutes — trial readouts, FDA decisions, and the deal math behind them. Free.
Subscribe →